Featured Research

from universities, journals, and other organizations

Blood-vessel Blocker Aids Cancer-killing Virus

Date:
November 28, 2007
Source:
Ohio State University
Summary:
Cancer-killing viruses are a promising therapy for incurable brain tumors, but their effectiveness has been limited in part because immune cells rapidly eliminate them. That immune response might be slowed, and the virus given more time to kill cancer cells, by blocking the growth of blood vessels in the tumor, new research suggests. The study indicates that pretreatment with a drug that blocks blood-vessel growth might improve the effectiveness of cancer-killing viruses.

Cancer-killing viruses are a promising therapy for incurable brain tumors, but their effectiveness has been limited in part because immune cells rapidly move in and eliminate them.

That immune response might be slowed, and the virus given more time to kill cancer cells, by blocking the growth of blood vessels in the tumor, new research here suggests.

The animal study, led by researchers at the Ohio State University Comprehensive Cancer Center, indicates that pretreatment with an antiangiogenic agent -- a drug that blocks blood-vessel growth -- might improve the effectiveness of cancer-killing viruses.

"Our work suggest that antiangiogenic agents can reduce virus-induced inflammation in brain-tumor tissue and improve the antitumor efficacy of oncolytic virus therapy by lengthening the time it takes the immune system to clear the virus," says principal investigator Balveen Kaur, assistant professor of neurological surgery.

"Much additional work is needed to validate these findings in other tumor models, but we hope that our findings will eventually be translated into clinical trials and one day help patients."

Kaur and her colleagues set out to learn how a cancer-killing, or oncolytic, virus affected the blood vessels in a brain-tumor model.

Kazuhiko Kurozumi, a visiting research scholar from Japan in Kaur's laboratory, first implanted rat glioma cells into the brains of several groups of rats. Seven days later, he injected a cancer-killing virus, called hrR3, into the growing tumors. This virus is a modified form of herpes simplex virus type 1 that reproduces and kills only tumor cells.

The virus caused the tumor blood vessels to become significantly more leaky compared with tumor blood vessels from control animals, and high numbers of white blood cells -- immune cells -- entered the tumor tissue.

The virus also triggered a twofold or greater change in the activity of 48 of 84 genes that are involved in inflammation and immune responses. Of those genes that were highly changed was the gene for interferon-gamma (IFNg), a substance important for coordinating immune responses to viral infections.

"Together, these findings indicate that the oncolytic virus triggered a local immune response in the tumor that would curtail its effectiveness," Kaur says.

In other rats, the researchers injected into developing tumors an agent that blocks blood-vessel growth. Four days after that, they injected the virus into the tumors. The agent is called cRGD (cyclic peptide of arginine-glycine-aspartic).

Tumors in animals that received the agent had significantly fewer blood vessels than control animals (28 vs. 62 per area of tumor), and the vessels were significantly less leaky. Also, fewer immune cells were drawn to the tumor from the bloodstream.

Furthermore, the treated animals showed a more than twofold drop in the activity of 19 genes associated with inflammation, including the gene for IFNg.

Finally, animals pretreated with the blood-vessel-growth inhibitor lived an average of 21 days, while control animals that received only the virus lived 17 days.

"The agent increased survival by about 23 percent," Kaur says, "which means a lot because these tumors are very aggressive.

The study is published online in the Journal of the National Cancer Institute with an accompanying editorial.

Funding from the National Brain Tumor Foundation, National Cancer Institute, and American Association for Neurological Surgeons/Congress of Neurological Surgeons, Section on Tumors/Brain Lab International Research Fellowship supported this research.


Story Source:

The above story is based on materials provided by Ohio State University. Note: Materials may be edited for content and length.


Cite This Page:

Ohio State University. "Blood-vessel Blocker Aids Cancer-killing Virus." ScienceDaily. ScienceDaily, 28 November 2007. <www.sciencedaily.com/releases/2007/11/071127161807.htm>.
Ohio State University. (2007, November 28). Blood-vessel Blocker Aids Cancer-killing Virus. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2007/11/071127161807.htm
Ohio State University. "Blood-vessel Blocker Aids Cancer-killing Virus." ScienceDaily. www.sciencedaily.com/releases/2007/11/071127161807.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins